The aim of this study was to assess the effect of volanesorsen on the corrected 
QT (QTc) interval. This thorough QT study enrolled 52 healthy male and female 
subjects who were randomized at a single site in a four-way crossover study. 
Subjects were randomly assigned to 1 of 12 treatment sequences and crossed over 
into four treatment periods over the course of which each subject was to receive 
a single therapeutic dose of volanesorsen as a 300 mg subcutaneous (SC) 
injection, a single supratherapeutic dose of volanesorsen as 300 mg intravenous 
(IV) infusion, a single oral (PO) dose of moxifloxacin (positive control), and 
placebo dose. The study demonstrated that volanesorsen 300 mg SC and 300 mg IV 
did not have a clinically relevant effect on ΔΔQTcF exceeding 10 ms. The largest 
mean effect at any postdose time point was 3.0 ms (90% confidence interval [CI]: 
0.8-5.2) after SC dosing and 1.8 ms (90% CI -0.4 to 4.0) after IV dosing. 
Volanesorsen, at the studied therapeutic and supratherapeutic doses, does not 
have a clinically meaningful effect on the QTc.